Volume 33, Issue 3 (10-2024)                   JGUMS 2024, 33(3): 298-309 | Back to browse issues page


XML Persian Abstract Print


Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:

Davoudi Kiakalayeh A, Mohtasham-Amiri Z, Karjooyan M, Davoudi Kiakalayeh S. Epidemiological Characteristics of Older Adults With COVID-19 in North of Iran (Guilan Province). JGUMS 2024; 33 (3) :298-309
URL: http://journal.gums.ac.ir/article-1-2660-en.html
1- Department of Preventive and Social Medicine, School of Medicine, Guilan University of Medical Sciences. Rasht, Iran.
2- Guilan Road Trauma Research Center, Trauma Institute, Guilan University of Medical Sciences, Rasht, Iran.
Full-Text [PDF 4091 kb]   (262 Downloads)     |   Abstract (HTML)  (1622 Views)
Full-Text:   (480 Views)
Introduction
Coronavirus is a type of virus belonging to the Coronaviridae family, which is phylogenetically classified into four groups: Alpha, Beta, Gamma, and Delta. The reservoirs of coronaviruses have been identified in mammals and birds, including bats, rodents, pigs, dogs, cattle, poultry, horses, and humans [۱]. A novel coronavirus, termed “SARS-CoV-2,” was first identified in Wuhan, China, on December 31, 2019, and was later designated as “COVID-19.” Human coronaviruses (HCoVs) are associated with a range of respiratory diseases of varying severity, including the common cold, pneumonia, and bronchitis [۲]. Individuals of all ages are susceptible to COVID-19; however, the risk of severe infections, complications, disabilities, and mortality is significantly higher in the elderly population [۳، ۴]. Physiological changes associated with aging, along with chronic diseases, such as cardiovascular and pulmonary conditions, diabetes, dementia, and polypharmacy, contribute to poor disease outcomes in older adults [۵].
Respiratory diseases typically exhibit a U-shaped mortality curve, with higher mortality rates observed among children and the elderly. However, in the case of COVID-19, this pattern differs, with mortality rates increasing significantly in older adults while children exhibit lower susceptibility to fatal outcomes [۶]. Various comorbidities, such as renal failure, diabetes, hypertension, arthritis, cardiovascular diseases, and chronic obstructive pulmonary disease are more prevalent in the elderly. The present study examines the epidemiological profile of COVID-19 in the elderly population of Guilan Province, Iran. The findings of this study provide valuable insights into infectious disease prevention and the development of targeted intervention programs for elderly populations, particularly during epidemic and pandemic periods.

Methods
This cross-sectional, multicenter study was designed based on the medical care monitoring center surveillance and registry system to assess the epidemiological profile of COVID-19 in Guilan  Province, Northern Iran, from March 2019 to March 2021. The study employed a census sampling approach, including all hospitalized elderly patients diagnosed with COVID-19 within the given time frame.
A checklist comprising different variables, such as age, sex, city of admission, disease onset date, clinical manifestations, underlying conditions, final health status, and vaccination history was completed by researchers in collaboration with healthcare professionals from the Deputy of Treatment at Guilan University of Medical Sciences. The data were entered into SPSS software, version 24 for statistical analysis.

Results
A total of 42481 elderly patients aged 60 years and above were hospitalized due to COVID-19 in Guilan  Province, Iran, over the 24-month study period. Among them, 22026(52%) were male, and 20455(48%) were female. Regarding age distribution, 18342(43%) patients belonged to the 60–69 age group (8864 females and 9478 males), 13 531(32%) were in the 70–79 age group (6 675 females and 6 856 males), 9 143(22%) were in the 80–89 age group (4273 females and 4870 males), and 1465 (3.5%) were aged 90 years and above (643 females and 822 males).
A chi-square statistical analysis revealed a significant association between age and sex among hospitalized patients (P<0.001). However, no significant association was found between mortality and sex (P>0.5). In contrast, a significant association was observed between mortality and age, with the probability of death increasing with advancing age (P<0.001).
Among all hospitalized elderly patients, 8176(19%) had received at least one dose of a COVID-19 vaccine at the time of admission. The highest vaccination rate was observed in patients aged 90 years and above (317 cases, 21%), while the lowest rate was recorded in the 60–69-year age group (3,329 cases, 18%). The most prevalent comorbidities among elderly COVID-19 patients were cardiovascular diseases and hypertension (10739 cases, 25.3%), followed by diabetes (10302 cases, 24.3%).
A chi-square analysis examining the relationship between clinical symptoms and mortality demonstrated a significant association between mortality and symptoms such as fever, myalgia, cough, respiratory distress, and decreased consciousness (P<0.001).

Conclusion
Overall, 13.9% of the elderly population aged 60 years and above in Guilan  Province were hospitalized due to COVID-19, with a higher hospitalization rate observed in males (9.78%) compared to females (8.52%). Guilan  Province (Iran) has a total elderly population of 465487 individuals, distributed as follows: 271578 in the 60–69-year age group, with 18 342 hospitalizations (6.75%); 131 411 in the 70–79-year age group, with 13531 hospitalizations (10.30%); 52801 in the 80–89-year age group, with 9143 hospitalizations (17.32%); and 9807 in the above 90-year age group, with 1465 hospitalizations (14.94%). The frequency of hospitalization increased with advancing age.
Among all hospitalized elderly patients, the highest vaccination rate (21%) was observed in individuals aged 90 years and above, while the lowest rate (18%) was recorded in the 60–69-year age group. This discrepancy may be attributed to national vaccination strategies prioritizing older age groups. Of the 42481 hospitalized elderly COVID-19 patients, 6289(14.8%) died. Among them, 3084(49%) had a positive polymerase chain reaction test result. Mortality rates among different age groups were as follows: 1099(51.6%) in the 60–69-year age group, 1044(50.8%) in the 70–79-year age group, 796(45.1%) in the 80–89 age group, and 145(42.1%) in the age group above 90 years.
This study highlights the increased vulnerability of the elderly to COVID-19, with advancing age correlating with higher infection and mortality rates. Male elderly individuals were at greater risk of infection compared to females. Additionally, the presence of comorbidities such as diabetes and cardiovascular diseases significantly impacted patient outcomes. Timely initiation of vaccination and achieving full coverage among high-risk groups remain crucial public health priorities during epidemics and pandemics. Training healthcare personnel in private hospitals to enhance preparedness during outbreaks is essential. Lastly, implementing a referral system within primary healthcare services is critical for reducing the burden on hospitals and optimizing healthcare resource utilization.

Ethical Considerations

Compliance with ethical guidelines

The study was approved by the Ethics Committee of Guilan University of Medical Sciences, Rasht, Iran (Code: IR.GUMS.REC.1401.295).

Funding
This research did not receive any grant from funding agencies in the public, commercial, or non-profit sectors.

Authors' contributions
Conceptualization and study design: Ali Davoudi Kiakalayeh, Zahra Mohtasham-Amiri; Data acquisition, analysis, and interpretation: Mehdi Karjooyan and Sajad Davoudi Kiakalayeh; Drafting of the manuscript: Ali Davoudi Kiakalayeh; Critical review of the manuscript for important intellectual content: Ali Davoudi Kiakalayeh; Statistical analysis: Sajad Davoudi Kiakalayeh; Supervision: Zahra Mohtasham-Amiri.

Conflicts of interest
The authors declared no conflict of interest.




References
  1. Zhang SF, Tuo JL, Huang XB, Zhu X, Zhang DM, Zhou K, et al. Epidemiology characteristics of human coronaviruses in patients with respiratory infection symptoms and phylogenetic analysis of HCoV-OC43 during 2010-2015 in Guangzhou. PLoS One. 2018; 13(1):e0191789. [DOI:10.1371/journal.pone.0191789] [PMID] [PMCID] 
  2. Banerjee A, Kulcsar K, Misra V, Frieman M, Mossman K. Bats and coronaviruses. Viruses. 2019; 11(1):41. [DOI:10.3390/v11010041] [PMID] [PMCID] 
  3. World Health Organization. Infection prevention and control during health care for probable or confirmed cases of Middle East respiratory syndrome coronavirus (‎‎ MERS-CoV)‎‎ infection: Interim guidance. Geneva: World Health Organization; 2019. [Link]
  4. Angeletti S, Benvenuto D, Bianchi M, Giovanetti M, Pascarella S, Ciccozzi M. COVID‐2019: The role of the nsp2 and nsp3 in its pathogenesis. Journal of Medical Virology. 2020; 92(6):584-8. [DOI:10.1002/jmv.25719] [PMID] [PMCID] 
  5. Nikolich-Zugich J, Knox KS, Rios CT, Natt B, Bhattacharya D, Fain MJ. SARS-CoV-2 and COVID-19 in older adults: What we may expect regarding pathogenesis, immune responses, and outcomes. Geroscience. 2020; 42(2):505-14. [DOI:10.1007/s11357-020-00186-0] [PMID] [PMCID] 
  6. Leung C. Risk factors for predicting mortality in elderly patients with COVID-19: A review of clinical data in China. Mechanisms of Ageing and Development. 2020; 188:111255. [DOI:10.1016/j.mad.2020.111255] [PMID] [PMCID] 
  7. Woolf SH, Chapman DA, Lee JH. COVID-19 as the leading cause of death in the United States. JAMA. 2021; 325(2):123-4. [DOI:10.1001/jama.2020.24865] [PMID] [PMCID] 
  8. Benksim A, Ait Addi R, Cherkaoui M. Vulnerability and fragility expose older adults to the potential dangers of COVID-19 pandemic. Iranian Journal of Public Health. 2020; 49(Suppl 1):122-4. [DOI:10.18502/ijph.v49iS1.3682] [PMID]
  9. Hosseininesar M, Zanjani H, Seyed Mirzaie SM, Kaldi A. [Study of quality of life of the elders in Gilan and its effective factors (Persian)]. Journal of Iranian Social Development Studies. 2018; 10(1):75-88. [Link]
  10. Sobotka T, Brzozowska Z, Muttarak R, Zeman K, Di Lego V. Age, gender and COVID-19 infections. MedRxiv. 2020. [DOI:10.1101/2020.05.24.20111765] 
  11. Cai Y, Kim DJ, Takahashi T, Broadhurst DI, Ma S, Rattray NJW, et al. Kynurenic acid underlies sex-specific immune responses to COVID-19. MedRxiv. 2020. [DOI:10.1101/2020.09.06.20189159] 
  12. Fink AL, Engle K, Ursin RL, Tang WY, Klein SL. Biological sex affects vaccine efficacy and protection against influenza in mice. Proceedings of the National Academy of Sciences of the United States of America. 2018; 115(49):12477-82. [DOI:10.1073/pnas.1805268115] [PMID] [PMCID] 
  13. Sharma G, Volgman AS, Michos ED. Sex differences in mortality from COVID-19 pandemic: Are men vulnerable and women protected? JACC. Case reports. 2020; 2(9):1407-10. [DOI:10.1016/j.jaccas.2020.04.027] [PMID] [PMCID] 
  14. Mohamed MS, Moulin TC, Schiöth HB. Sex differences in COVID-19: The role of androgens in disease severity and progression. Endocrine. 2021; 71(1):3-8. [DOI:10.1007/s12020-020-02536-6] [PMID] [PMCID] 
  15. Li XN, Huang Y, Wang W, Jing QL, Zhang CH, Qin PZ, et al. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: A test-negative case-control real-world study. Emerging Microbes & Infections. 2021; 10(1):1751-9. [DOI:10.1080/22221751.2021.1969291] [PMID] [PMCID] 
  16. Bernal JL, Andrews N, Gower C, Gallagher E, Simmons R, Thelwall S, et al. Effectiveness of COVID-19 vaccines against the B. 1.617. 2 (Delta) variant. The New England Journal of Medicine. 2021; 385(7):585-94. [DOI:10.1101/2021.05.22.21257658] 
  17. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization. Nature. 2021; 596(7871):276-80. [DOI:10.1038/s41586-021-03777-9] [PMID] 
  18. Tada T, Zhou H, Dcosta BM, Samanovic MI, Mulligan MJ, Landau NR. The spike proteins of SARS-CoV-2 B. 1.617 and B. 1.618 variants identified in India provide partial resistance to vaccine-elicited and therapeutic monoclonal antibodies. BioRxiv. 2021. [DOI:10.1101/2021.05.14.444076] 
  19. Lascarrou JB , Colin G,Thuaut AL, Serck N , Ohana M, Sauneuf B, et al,  Predictors of negative first SARS-CoV-2 RT-PCR despite final diagnosis of COVID-19 and association with outcome. Scientific Reports. 2021; 11(1):2388. [PMID]
  20. Gupta-Wright A, Macleod CK, Barrett J, Filson SA, Corrah T, Parris V, et al. False-negative RT-PCR for COVID-19 and a diagnostic risk score: A retrospective cohort study among patients admitted to hospital. BMJ Open. 2021; 11(2):e047110. [DOI:10.1136/bmjopen-2020-047110] [PMID] [PMCID] 
  21. Atkins JL, Masoli JAH, Delgado J, Pilling LC, Kuo CL, Kuchel GA, ed al. Preexisting comorbidities predicting severe COVID-19 in older adults in the UK Biobank community cohort. medRxiv. 2020. [DOI:10.1101/2020.05.06.20092700] 
  22. Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: A descriptive study. Lancet. 2020; 395(10223):507-13. [DOI:10.1016/S0140-6736(20)30211-7] [PMID] 
  23. Gu T, Mack JA, Salvatore M, Prabhu Sankar S, Valley TS, Singh K, et al. Characteristics associated with racial/ethnic disparities in COVID-19 outcomes in an academic health care system. JAMA Network Open. 2020; 3(10):e2025197.[DOI:10.1001/jamanetworkopen.2020.25197] [PMID] [PMCID] 
  24. Holman N, Knighton P, Kar P, O›Keefe J, Curley M, Weaver A, et al. Risk factors for COVID-19-related mortality in people with type 1 and type 2 diabetes in England: A population-based cohort study. The lancet. Diabetes & Endocrinology. 2020; 8(10):823-33. [DOI:10.1016/S2213-8587(20)30271-0] [PMID] 
  25. Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ, ET AL. COVID-19: Consider cytokine storm syndromes and immunosuppression. Lancet. 2020; 395(10229):1033-4. [DOI:10.1016/S0140-6736(20)30628-0] [PMID]
  26. Wang L, He W, Yu X, Hu D, Bao M, Liu H, et al. Coronavirus disease 2019 in elderly patients: Characteristics and prognostic factors based on 4-week follow-up. The Journal of Infection. 2020; 80(6):639-45. [DOI:10.1016/j.jinf.2020.03.019] [PMID] [PMCID] 
  27. Hase R, Kurita T, Muranaka E, Sasazawa H, Mito H, Yano Y. A case of imported COVID-19 diagnosed by PCR-positive lower respiratory specimen but with PCR-negative throat swabs. Infectious Diseases. 2020; 52(6):423-6. [DOI:10.1080/23744235.2020.1744711] [PMID] [PMCID] 
  28. Kim ES, Chin BS, Kang CK, Kim NJ, Kang YM, Choi JP, et al. Clinical course and outcomes of patients with severe acute respiratory syndrome coronavirus 2 infection: A preliminary report of the first 28 patients from the Korean cohort study on COVID-19. Journal of Korean Medical Science. 2020; 35(13):e142.[DOI:10.3346/jkms.2020.35.e142] [PMID] [PMCID] 
  29. Yi Y, Lagniton PNP, Ye S, Li E, Xu RH. COVID-19: What has been learned and to be learned about the novel coronavirus disease. International Journal of Biological Sciences. 2020; 16(10):1753-66. [DOI:10.7150/ijbs.45134] [PMID] [PMCID] 
  30. Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9.  [DOI:10.1001/jama.2020.1585] [PMID] [PMCID] 
  31. Davoudi-Kiakalayeh A, Dalal K, Yousefzade-Chabok S, Jansson B, Mohammad R. Costs related to drowning and near drowning in Northern Iran (Guilan province). Ocean & Coastal Management. 2011; 54(3):250-5‏. [DOI:10.1016/j.ocecoaman.2010.12.004]
  32. Homaie Rad E, Hajizadeh M, Rezaei S, Reihanian A, Ehsani- Chimeh E, Davoudi- Kiakalayeh A. Utilization and expenditures on traditional and herbal medicines in Iran: 2009–2016. Journal of Herbal Medicine. 2021; 25:100414. [DOI:10.1016/j.hermed.2020.100414]
Review Paper: Research | Subject: Special
Received: 2023/11/6 | Accepted: 2024/02/29 | Published: 2024/10/1

Add your comments about this article : Your username or Email:
CAPTCHA

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | Journal of Guilan University of Medical Sciences

Designed & Developed by : Yektaweb